Finance

Lists
Q3 2026 earnings • released • EPS beat +21.95%
See results
BLTE:NASDAQ
Belite Bio Inc
$169.96
+8.99%
(+14.02) 1D
$172.80
+1.67% (+2.84)
Pre-market
Closed: Nov 12, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLTE...
Open
$157.31
High
$170.89
Low
$149.78
Mkt. cap
6.84B
Avg. vol.
165.51K
Volume
489.00
52-wk high
$200.00
52-wk low
$105.88
EPS
-$2.85
Beta
-1.19
Shares outstanding
40.27M
No. of employees
41
Open
$157.31
High
$170.89
Low
$149.78
Mkt. cap
6.84B
Avg. vol.
165.51K
Volume
489.00
52-wk high
$200.00
52-wk low
$105.88
EPS
-$2.85
Beta
-1.19
Shares outstanding
40.27M
No. of employees
41
News stories
From web sources and news partners
About Belite Bio Inc
CEO-
Employees41
Founded2016
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitebelitebio.com
Analyst ratings
Based on 7 analysts giving stock ratings to BLTE in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for BLTE in the last 3 months.
Highest
Current $169.96
$303.00 (+78.28%)
Average
$235.00 (+38.27%)
Lowest
$200.00 (+17.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$221.00
+30%
10/29/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$245.00
+44.2%
10/15/2026
Whitney Ijem
Canaccord Genuity
Buy
Initiated
$303.00
+78.3%
09/04/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
$200.00
+17.7%
09/02/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$206.00
+21.2%
08/17/2026
Michael Okunewitch
Maxim Group
Buy
Maintained
$200.00
+17.7%
08/14/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$270.00
+58.9%
08/14/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
$217.00
+27.7%
03/03/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.60 / -$0.77
+21.95%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10.31M
14.62M
15.66M
18.21M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12.71M
13.45M
17.02M
16.69M
Operating expense
23.02M
28.08M
32.68M
34.91M
Total operating expenses
23.02M
28.08M
32.68M
34.91M
Operating income
-23.02M
-28.08M
-32.68M
-34.91M
Other non operating income
-2.14M
-417.00K
5.75M
6.55M
EBT including unusual items
-21.69M
-25.32M
-26.94M
-28.36M
EBT excluding unusual items
-21.69M
-25.32M
-26.94M
-28.36M
Income tax expense
-
-
-
55.00K
Effective tax rate
-
-
-
-0.19%
Other operating expenses
-
-
-
-
Net income
-21.69M
-25.32M
-26.94M
-28.41M
Net profit margin
-
-
-
-
Earnings per share
-0.65
-0.70
-0.68
-0.70
Interest and investment income
3.47M
3.17M
-
-
Interest expense
-
-2.00K
-
-
Net interest expenses
3.47M
3.17M
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.97M
-28.03M
-32.64M
-34.86M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps